Results 1 to 10 of about 108,380,509 (205)

Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors [PDF]

Molecules, 2020
Aprepitant, a lipophilic and small molecular representative of neurokinin 1 receptor antagonists, is known for its anti-proliferative activity on numerous cancer cell lines that are sensitive to Substance P mitogen action.
Paweł K. Halik, Piotr F. J. Lipiński, Joanna Matalińska, Przemysław Koźmiński, Aleksandra Misicka, Ewa Gniazdowska   +5 more
doaj   +4 more sources

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database [PDF]

Frontiers in Pharmacology
BackgroundAprepitant, fosaprepitant, and netupitant are three common neurokinin-1 receptor antagonists (NK-1RAs) used to prevent chemotherapy-induced nausea and vomiting, following highly or moderately emetogenic chemotherapy.
Chuanli Yang, Chuanli Yang, Chuanli Yang, Pengyang Xu, Teng Wu, Yunhe Fan, Qingqing Li, Jijun Zhang, Xiaobing Shen, Xiaobing Shen, Xiushan Dong   +10 more
doaj   +4 more sources

Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine [PDF]

Archives of Razi Institute, 2021
Substance P binds to the Neurokinin-1 (NK-1) receptors found in the emetic center of the central nervous system (CNS) to induce emesis. Maropitant is a selective NK-1 receptor antagonist that inhibits the binding of substance P to NK-1 receptors and is ...
K Sharun, K Jambagi, M Arya, . Aakanksha, S. N Chaithra, P. K Patel, S. K Dixit, K Dhama   +7 more
doaj   +2 more sources

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis [PDF]

BMC Cancer, 2022
Background Olanzapine has been reported to be an effective antiemetic in patients receiving carboplatin-based chemotherapy. However, the efficacy of a neurokinin-1 receptor antagonist (NK1RA) added to olanzapine, a 5-hydroxytryptamine-3 receptor ...
Senri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, Hitoshi Kawazoe, Kazuki Tanaka, Yukiyoshi Fujita, Masakazu Abe, Hisao Imai, Masato Karayama, Yoh Hayasaki, Chiemi Hirose, Takafumi Suda, Kazuto Nakamura, Akio Suzuki, Yasushi Ohno, Ken-ichirou Morishige, Naoki Inui   +16 more
doaj   +2 more sources

The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors

Current Oncology, 2021
Rhabdoid tumors (RT) are among the most aggressive tumors in early childhood. Overall survival remains poor, and treatment only effectively occurs at the cost of high toxicity and late adverse effects. It has been reported that the neurokinin-1 receptor/
Julian Kolorz, Salih Demir, Adrian Gottschlich, Iris Beirith, Matthias Ilmer, Daniel Lüthy, Christoph Walz, Mario M. Dorostkar, Thomas Magg, Fabian Hauck, Dietrich von Schweinitz, Sebastian Kobold, Roland Kappler, Michael Berger   +13 more
doaj   +2 more sources

Involvement of neurokinin-1 receptors in the autonomic nervous system in colorectal distension-induced cardiovascular suppression in rats [PDF]

Frontiers in Pharmacology, 2022
Situational syncope, which includes rectally mediated reflexes, is defined as syncope induced by a specific situation. Its pathogenesis generally involves disorders of the autonomic nervous system.
Kentaro Kurogochi, Kentaro Kurogochi, Masami Uechi, Kensuke Orito   +3 more
doaj   +2 more sources

Evaluation of the Antinociceptive Effect of Maropitant, a Neurokinin-1 Receptor Antagonist, in Cats Undergoing Ovariohysterectomy [PDF]

Veterinary Medicine International, 2019
Maropitant is a neurokinin-1 (NK1) receptor antagonist that can be used for pain management. The objective of this study was to evaluate the effect of continuous infusion of two doses of maropitant on cardiorespiratory parameters and its postoperative ...
Janaina M. X. Corrêa, Priscila C. L. R. Soares, Raquel V. Niella, Brenda A. Costa, Maxuel S. Ferreira, Alex C. Silva Junior, Aline S. Sena, Kátia M. O. R. Sampaio, Elisângela B. Silva, Fabiana L. Silva, Mário S. L. Lavor   +10 more
doaj   +2 more sources

In Vitro Biological Evaluation of Aprepitant Based ¹⁷⁷Lu-Radioconjugates

Pharmaceutics, 2022
Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed.
Paweł K. Halik, Przemysław Koźmiński, Joanna Matalińska, Piotr F. J. Lipiński, Aleksandra Misicka, Ewa Gniazdowska   +5 more
doaj   +1 more source

Effectiveness of aprepitant in post‐acute COVID19 syndrome

Clinical Case Reports, 2021
This is the first case of a patient taking aprepitant for a post‐acute COVID‐19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.
Rocío Reinoso‐Arija, Cecilia López‐Ramírez, José Antonio Jimenez‐Ruiz, José Luis López‐Campos   +3 more
doaj   +1 more source

Substance P Increases the Excitability of Dorsal Motor Nucleus of the Vagus Nerve via Inhibition of Potassium Channels

Frontiers in Neuroscience, 2022
Increases in the substance P (SP) concentration in the medial portion of the dorsal motor nucleus of the vagus nerve (mDMV) in the brainstem are closely associated with chemotherapy induced nausea and vomiting (CINV). However, the underlying cellular and
Eunhee Yang, Woojin Kim, Yong Seek Park, Young-Ho Jin   +3 more
doaj   +1 more source